Perceptive Advisors’s Theravance Biopharma TBPH Stock Holding History

Perceptive Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,000,000	Closed	-$23.1M	–	139
2020 Q1	$23.1M	Buy	+1,000,000	New	+$25M	0.6%	40

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors's TBPH Position: Q2 2020 in Review

Perceptive Advisors sold out of Theravance Biopharma (TBPH) in Q2 2020, closing a stake of 1,000,000 shares — an estimated $23.1M sold.

Perceptive Advisors first reported a position in TBPH in Q1 2020 and held it in 1 quarter. The position peaked at $23.1M in Q1 2020. 125 funds tracked by Wall St. Rank hold TBPH as of Q2 2020.

Perceptive Advisors reported no remaining Theravance Biopharma position as of Q2 2020 after selling out during the quarter.
Perceptive Advisors sold 1,000,000 Theravance Biopharma shares in Q2 2020, an estimated $23.1M.
Perceptive Advisors first reported a position in Theravance Biopharma in Q1 2020 and held it in 1 quarter.
Perceptive Advisors's Theravance Biopharma position peaked at $23.1M in Q1 2020.
125 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2020.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.